Preferences and Trends in the Treatment of Diabetic Retinopathy in Korea and Japan
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Jung Yup | - |
dc.contributor.author | Shin, Jae Pil | - |
dc.contributor.author | Jo, Young Joon | - |
dc.contributor.author | Park, Tae Kwann | - |
dc.contributor.author | Yu, Seung Young | - |
dc.contributor.author | Chang, Woo Hyok | - |
dc.contributor.author | Oh, Jae Ryung | - |
dc.contributor.author | Lee, Ji Eun | - |
dc.contributor.author | Lee, Joo Eun | - |
dc.date.accessioned | 2021-09-03T21:18:17Z | - |
dc.date.available | 2021-09-03T21:18:17Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2016-08 | - |
dc.identifier.issn | 0378-6471 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/87873 | - |
dc.description.abstract | Purpose: To evaluate preferences and trends in the management of diabetic retinopathy in Korea and Japan. Methods: An Internet survey comprised of 49 questions was sent to the members of Korean Retina Society (KRS) and Japanese Society of Ophthalmic Diabetology (JSOD). The survey was conducted during the period between June 2012 and July 2012. Results: Ninety-one of 210 members of the KRS (43%) and 120 of 754 members of the JSOD (16%) participated in the survey. For diffuse diabetic macular edema, Intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) followed by focal laser treatment' was the most preferred treatment in Korea (48%), while 'sub-tenon steroid injection followed by focal laser treatment' was the most common procedure in Japan (33%). Vitrectomy was the second most common procedure in Japan (18%). In contrast, none of the KRS members preferred vitrectomy in this situation. For refractory diabetic macular edema, however, vitrectomy with or without the use of anti-VEGF was chosen in 75% of the KRS members. In Japan, vitrectomy without the use of intravitreal injection of anti-VEGF or steroid was relatively more preferred. Small-gauge (G) vitrectomy using either a 23 G or 25 G needle was popular in both countries (90% in Korea, 64% in Japan). Conclusions: Although the trends in diagnostic and surgical environments were similar in Korea and Japan, the preferred treatment approaches for diabetic macular edema were different. Sub-tenon steroid injection and vitrectomy were preferred in Japan, while anti-VEGF injection was most commonly employed in Korea. | - |
dc.language | Korean | - |
dc.language.iso | ko | - |
dc.publisher | KOREAN OPHTHALMOLOGICAL SOC | - |
dc.title | Preferences and Trends in the Treatment of Diabetic Retinopathy in Korea and Japan | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Oh, Jae Ryung | - |
dc.identifier.doi | 10.3341/jkos.2016.57.8.1248 | - |
dc.identifier.wosid | 000471587100010 | - |
dc.identifier.bibliographicCitation | JOURNAL OF THE KOREAN OPHTHALMOLOGICAL SOCIETY, v.57, no.8, pp.1248 - 1253 | - |
dc.relation.isPartOf | JOURNAL OF THE KOREAN OPHTHALMOLOGICAL SOCIETY | - |
dc.citation.title | JOURNAL OF THE KOREAN OPHTHALMOLOGICAL SOCIETY | - |
dc.citation.volume | 57 | - |
dc.citation.number | 8 | - |
dc.citation.startPage | 1248 | - |
dc.citation.endPage | 1253 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002132786 | - |
dc.description.journalClass | 2 | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Ophthalmology | - |
dc.relation.journalWebOfScienceCategory | Ophthalmology | - |
dc.subject.keywordAuthor | Diabetic retinopathy | - |
dc.subject.keywordAuthor | Japan | - |
dc.subject.keywordAuthor | Korea | - |
dc.subject.keywordAuthor | Preferences and trends survey | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.